Congress
$1,001–$15,000
Traded Nov 13, 2025 · disclosed 28 days laterJoint
5 different filers disclosed MRK within 90 days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 10, 2025 · Filed Nov 12, 2025
Merck's Chief Comm. & Public Afrs Ofcr sold $616K of Merck shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$616,395
Shares × reported transaction price
11 days after results of Oct 30, 2025, 85 days before results of Feb 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $86.75 on Nov 10, 2025, 18% above its 52-week low and 16% below its high, after a 10% rise over the previous 30 trading days
52-week range $73.47 (May 14, 2025) to $103.79 (Dec 9, 2024), 44% of the way up, from 250 adjusted closes. 30 trading days earlier: $78.58 on Sep 29, 2025. Describes the past only, not a forecast
RSI 55, 3% above its 200-day average, 2% above its 50-day average, 16% below the 52-week high, 20-day volatility 21% a year, against the S&P 500: −3 points over 1 month, +2 points over 3 months, −9 points over 6 months
From the adjusted closes up to Nov 10, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Feb 12, 2025 in the U.S. District Court, D. New Jersey. A filing is an allegation, not a finding.
IN RE MERCK & CO., INC. SECURITIES LITIGATION, docket 2:25-cv-01208, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Keytruda on Nov 21, 2025, 11 days after this trade.
New use approved (efficacy supplement). Active ingredient: Pembrolizumab. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.2% | −2.9% | +5.1% |
| 30 days | +7.9% | +1.3% | +6.6% |
| 90 days | +28.4% | +3.0% | +25.4% |
| 180 days | +20.9% | +9.8% | +11.1% |
| 365 days | +59.0% | +12.3% | +46.8% |
Past results only. Not a forecast.
Congress
Traded Nov 13, 2025 · disclosed 28 days laterJoint
5 different filers disclosed MRK within 90 days.
Fund moves
95 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 1, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
7 tracked managers disclosed the same change for Q2 2025. From a 13F filed Nov 14, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.